185 related articles for article (PubMed ID: 30352966)
1. Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells.
Skalniak L; Kocik J; Polak J; Skalniak A; Rak M; Wolnicka-Glubisz A; Holak TA
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30352966
[TBL] [Abstract][Full Text] [Related]
2. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
Khurana A; Shafer DA
Onco Targets Ther; 2019; 12():2903-2910. PubMed ID: 31289443
[TBL] [Abstract][Full Text] [Related]
3. Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists.
Kocik J; Machula M; Wisniewska A; Surmiak E; Holak TA; Skalniak L
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31331108
[TBL] [Abstract][Full Text] [Related]
4. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
[TBL] [Abstract][Full Text] [Related]
5. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
9. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
Van Goethem A; Yigit N; Moreno-Smith M; Vasudevan SA; Barbieri E; Speleman F; Shohet J; Vandesompele J; Van Maerken T
Oncotarget; 2017 Aug; 8(34):57047-57057. PubMed ID: 28915653
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
13. A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53
Skalniak L; Twarda-Clapa A; Neochoritis CG; Surmiak E; Machula M; Wisniewska A; Labuzek B; Ali AM; Krzanik S; Dubin G; Groves M; Dömling A; Holak TA
FEBS J; 2019 Apr; 286(7):1360-1374. PubMed ID: 30715803
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.
Zanjirband M; Curtin N; Edmondson RJ; Lunec J
Oncotarget; 2017 Sep; 8(41):69779-69796. PubMed ID: 29050241
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
[TBL] [Abstract][Full Text] [Related]
16. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.
Marcellino BK; Farnoud N; Cassinat B; Lu M; Verger E; McGovern E; Patel M; Medina-Martinez J; Levine MF; Arango Ossa JE; Zhou Y; Kosiorek H; Mehrotra M; Houldsworth J; Dueck A; Rossi M; Mascarenhas J; Kiladjian JJ; Rampal RK; Hoffman R
Blood Adv; 2020 Nov; 4(22):5735-5744. PubMed ID: 33216890
[TBL] [Abstract][Full Text] [Related]
17. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ; Yu LJ; Reddy MB; Fretland AJ; Parrott N; Hussain S; Palacios M; Vazvaei F; Zhi J; Tuerck D
Xenobiotica; 2016 Aug; 46(8):667-76. PubMed ID: 26586447
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
Drummond CJ; Esfandiari A; Liu J; Lu X; Hutton C; Jackson J; Bennaceur K; Xu Q; Makimanejavali AR; Del Bello F; Piergentili A; Newell DR; Hardcastle IR; Griffin RJ; Lunec J
Oncotarget; 2016 Jul; 7(29):46203-46218. PubMed ID: 27323823
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
20. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
